Vol. 3 No. 4 (2023)
Reimbursement Reviews

Lurbinectedin (Zepzelca)

decorative image

Published April 17, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses lurbinectedin (Zepzelca) for injection, lyophilized powder, 4 mg/vial, IV infusion.
  • Indication: Treatment of adult patients with stage III or metastatic small cell lung cancer who have progressed on or after platinum-containing therapy.